Evidence map›Paper›PMID 40681103›Full record

ArticleMolecular metabolism2025

Mitochondrial-targeted plastoquinone therapy prevents early onset muscle weakness that occurs before atrophy during ovarian cancer.

Luca J Delfinis, Shahrzad Khajehzadehshoushtar, Luke D Flewwelling, Nathaniel J Andrews, Madison C Garibotti, Shivam Gandhi, Aditya N Brahmbhatt, Brooke A Morris, Bianca Garlisi, Sylvia Lauks and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Luca J DelfinisSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, M3J 1P3, Canada. Electronic address: delfinis@yorku.ca.
Shahrzad KhajehzadehshoushtarSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, M3J 1P3, Canada. Electronic address: sshoush@yorku.ca.
Luke D FlewwellingSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, M3J 1P3, Canada. Electronic address: lukedf@yorku.ca.
Nathaniel J AndrewsSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, M3J 1P3, Canada. Electronic address: joela9@yorku.ca.
Madison C GaribottiSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, M3J 1P3, Canada. Electronic address: mgarib@yorku.ca.
Shivam GandhiSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, M3J 1P3, Canada. Electronic address: shivamg@yorku.ca.
Aditya N BrahmbhattSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, M3J 1P3, Canada. Electronic address: anbrahm4@yorku.ca.
Brooke A MorrisSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, M3J 1P3, Canada. Electronic address: brookeam@yorku.ca.
Bianca GarlisiDepartment of Biomedical Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada. Electronic address: bgarlisi@uoguelph.ca.
Sylvia LauksDepartment of Biomedical Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada. Electronic address: slauks@uoguelph.ca.
Caroline AitkenDepartment of Biomedical Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada. Electronic address: caitke01@uoguelph.ca.
Leslie OgilvieDepartment of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada. Electronic address: ogilviel@uoguelph.ca.
Stavroula TsitkanouCachexia Research Laboratory, Department of Health, Human Performance and Recreation, College of Education and Health Professions, University of Arkansas, Fayetteville, AR, 71656, USA. Electronic address: st060@uark.edu.
Jeremy A SimpsonDepartment of Human Health and Nutritional Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada. Electronic address: jeremys@uoguelph.ca.
Nicholas P GreeneCachexia Research Laboratory, Department of Health, Human Performance and Recreation, College of Education and Health Professions, University of Arkansas, Fayetteville, AR, 71656, USA. Electronic address: npgreene@uark.edu.
Arthur J ChengSchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, M3J 1P3, Canada. Electronic address: ajcheng@yorku.ca.
Jim PetrikDepartment of Biomedical Sciences, University of Guelph, Guelph, ON, N1G 2W1, Canada. Electronic address: jpetrik@uoguelph.ca.
Christopher G R PerrySchool of Kinesiology & Health Science, Muscle Health Research Centre, York University, Toronto, ON, M3J 1P3, Canada. Electronic address: cperry@yorku.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMuscle loss with cancer causes weakness, worsens quality of life, and predicts reduced overall survival rates. Recently, muscle weakness was identified during early-stage cancer before atrophy develops. This discovery indicates that mechanisms independent of muscle loss must contribute to progressive weakness. While mitochondrial stress responses are associated with early-stage 'pre-cachexia' weakness, a causal relationship has not been established. METHODS AND

resultsHere, using a mouse model of metastatic ovarian cancer cachexia, we identified that the well-established mitochondrial-targeted plastoquinone SkQ1 partially prevents muscle weakness occurring before the development of atrophy in the diaphragm. Furthermore, SkQ1 improved force production during atrophy without preventing atrophy itself in the tibialis anterior and diaphragm. These findings indicate that atrophy-independent mechanisms of muscle weakness occur in different muscle types throughout ovarian cancer. Ovarian cancer reduced flexor digitorum brevis (FDB) whole muscle force production and myoplasmic free calcium ([Ca

conclusionsThese discoveries identify that muscle weakness can occur independent of atrophy throughout ovarian cancer in a manner that is linked to improved calcium handling. The findings also demonstrate that mitochondrial-targeted therapies exert a robust effect in preserving muscle force early during ovarian cancer during the pre-atrophy period and in late stages once cachexia has become severe.

Indexed as

MitochondriaMuscle WeaknessMuscular AtrophyOvarian NeoplasmsPlastoquinoneAnimalsCachexiaCalciumDisease Models, AnimalFemaleHumansMiceMice, Inbred C57BLMuscle, Skeletal10-(6'-plastoquinonyl)decyltriphenylphosphoniumCalciumPlastoquinoneMitochondriaOvarian cancer cachexiaSkeletal muscle

Identifiers

PMID40681103
PMCPMC12340566

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.